



healthcare ltd.

April 05, 2021

To,  
The Manager  
Listing Department,  
**The National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

**Trading Symbol: ZOTA**

**Sub: Product Registration in Cambodia**

**Ref.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we would like to inform you that we, Zota Health Care Limited (the "Company") have received product registration licenses for below mentioned two products from the Ministry of Health, Cambodia.

Sr. No.	Name of Product	Therapeutic Category
1	Zotalan 30 (Tablet – Each tablet contains Lansoprazole 30mg)	PPI
2	RTFIT (Tablet – Each tablet contains Taurine 500mg and Racemethionine 200mg)	Patented drug for Liver ailment

We have received licenses for the aforementioned products for the validity period of five years; licenses for the products are also renewable. Company shall start exporting these products in Cambodia very soon.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zota Health Care Limited

**Ashvin Variya**  
**(Company Secretary & Compliance Officer)**  
Place: Surat



**Registered Office :**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601  
Email: info@zotahealthcare.com  
Web : www.zotahealthcare.com

**Plant :**

Plot no. 169, Surat Special Economic Zone,  
Nr. Sachin Railway Station, Sachin,  
Surat - 394 230 (Guj.) India  
Ph: +91 261 2397122